global pharmacogenomics (pgx) market analysis, estimation & forecast 2016-2022

1Contact: [email protected]

Global Pharmacogenomics (PGx) Market Analysis: Focus On Ecosystem Players (Diagnostic Test, Pharmaceutical & Others), Therapeutic Applications (Oncology, Cardiovascular & Others), and Geography

– Estimation & Forecast 2016-2022

Contact: [email protected]

BIS Research is a leading market intelligence and technology research company. BIS Research publishes

in-depth market intelligence reports focusing on the market estimations, technology analysis, emerging

high-growth applications, deeply segmented granular country-level market data and other important

market parameters useful in the strategic decision making for senior management. BIS Research

provides multi-client reports, company profiles, databases, and custom research services.

Copyright © 2016 BIS Research

All Rights Reserved. This document contains highly confidential information and is the sole property of

BIS Research. Disclosing, copying, circulating, quoting or otherwise reproducing any or all contents of

this document is strictly prohibited. Access to this information is provided exclusively for the benefit of

the people or organization concerned. It may not be accessed by, or offered whether for sale or

otherwise to any third party.

2

TABLE OF CONTENT

SR. NO CONTENTS PAGE NO.

1 REPORT OVERVIEW 38

1.1 REPORT SCOPE 39

1.1.1 REPORT COVERAGE 39

1.1.2 ASSUMPTIONS AND LIMITATIONS 40

1.1.3 MARKET CLASSIFICATION & SEGMENTATION 41

1.2 RESEARCH METHODOLOGY 42

1.2.1 DATA POINTS CONSIDERED FOR MARKET SIZE ESTIMATION 43

1.2.2 KEY DATA POINT SOURCES 44

1.2.2.1 KEY DATA POINTS FROM PRIMARY SOURCES 44

1.2.2.2 KEY DATA POINTS FROM SECONDARY SOURCES 45

1.2.3 DATA TRIANGULATION 46

1.2.4 TOP-DOWN APPROACH 47

1.2.5 BOTTOM-UP APPROACH 48


TABLE OF CONTENT


1.3 REPORT DESCRIPTION 49

2 EXECUTIVE SUMMARY 51

2.1 GLOBAL MARKET SCENARIO 52

3 MARKET OVERVIEW 55

3.1 INTRODUCTION 56

3.2 PHARMACOGENOMICS: MECHANISM OF ACTION 58

3.3 ROLE OF COMPANION DIAGNOSTICS IN PGX 59

3.4 ROLE OF BIOMARKERS IN PGX 60

3.5 ROLE OF MOLECULAR DIAGNOSTICS IN PGX 61

3.6 BENEFITS OF PGX 62

3.7 END-USE APPLICATIONS OF PGX 63

3.8 MARKET DYNAMICS 64

3.8.1 MARKET DRIVERS 65


TABLE OF CONTENT


3.8.2 MARKET CHALLENGES 67

3.8.3 MARKET OPPORTUNITIES 69

4 COMPETITIVE INSIGHTS 70

4.1 KEY MARKET DEVELOPMENTS & STRATEGIES 71

4.1.1 COMPETITIVE LANDSCAPE OF SOME OF THE KEY PLAYERS 72

4.1.2 PARTNERSHIPS, JOINT VENTURES AND COLLABORATIONS 73

4.1.2.1 KEY INSIGHTS 73

4.1.2.2 RECENT PARTNERSHIPS, JOINT VENTURES AND COLLABORATIONS 74

4.1.3 PRODUCT LAUNCH AND DEVELOPMENTS 77


4.1.3.2 RECENT PRODUCT LAUNCH AND DEVELOPMENTS 78

4.1.4 PATENTS, LICENSING, CERTIFICATION AND APPROVALS 81


4.1.4.2 RECENT PATENTS, LICENSING, CERTIFICATION AND APPROVALS 82


TABLE OF CONTENT


4.1.5 MERGERS AND ACQUISITIONS 85


4.1.5.2 RECENT MERGERS AND ACQUISITIONS 86

4.1.6 BUSINESS CONTRACTS AND BUSINESS EXPANSIONS 88


4.1.6.2 RECENT BUSINESS CONTRACTS AND BUSINESS EXPANSIONS 89

4.1.7 OTHER STRATEGIES 91


4.1.7.2 RECENT DEVELOPMENTTS OF OTHER STRATEGIES 92

4.2 PORTER’S FIVE FORCES ANALYSIS 94

4.2.1 THREAT OF SUBSTITUTES 95

4.2.2 THREAT OF NEW ENTRANTS 97

4.2.3 BARGAINING POWER OF BUYERS 99

4.2.4 BARGAINING POWER OF SUPPLIERS 101

4.2.5 INTENSITY OF COMPETITIVE RIVALRY 103


TABLE OF CONTENT


5 INDUSTRY ANALYSIS 105

5.1 PATENT ANALYSIS 106

5.1.1 SOME OF THE KEY PLAYERS 106

5.1.2 OTHERS (UNIVERSITY/HOSPITAL/PERSON) 109

5.2 REGULATIONS, CONSORTIUMS, CERTIFICATIONS, & STANDARDS 112

5.2.1 REGULATORY BODIES 117

5.2.2 EXAMPLES OF SOME COMMON ACTS CERTIFICATIONS 121

5.3 VALUE CHAIN ANALYSIS 123

6 GLOBAL PHARMACOGENOMICS MARKET BY TECHNOLOGY 124

6.1 MARKET SEGMENTATION BY TECHNOLOGY 125

6.2 MICROARRAY 126

6.2.1 INTRODUCTION 126

6.2.2 MICROARRAY: TYPES, APPLICATIONS & KEY PLAYERS 127

6.2.3 MICROARRAY: MARKET DYNAMICS & RECENT DEVELOPMENTS 128


TABLE OF CONTENT


6.3 SEQUENCING 129


6.3.2 SEQUENCING: MARKET DYNAMICS, APPLICATIONS & KEY PLAYERS 130

6.3.3 TYPES OF SEQUENCING TECHNOLOGIES 131

6.3.3.1 SANGER SEQUENCING 131

6.3.3.2 PYROSEQUENCING 131

6.3.3.3 NEXT-GEN SEQUENCING (NGS) 132

6.3.3.3.1 NEXT-GEN SEQUENCING (NGS) APPLICATIONS & KEY PLAYERS 133

6.3.3.3.2 NEXT-GEN SEQUENCING (NGS) RECENT DEVELOPMENTS 134

6.4 POLYMERASE CHAIN REACTION (PCR) 135


6.4.2 PCR TYPES 136

6.4.3 PCR: MARKET DYNAMICS, APPLICATIONS & KEY PLAYERS 137


TABLE OF CONTENT


6.5 OTHER TECHNOLOGIES 138

6.5.1 MASS SPECTROMETRY 138

6.5.2 ELECTROPHORESIS 139

7 GLOBAL PHARMACOGENOMICS MARKET BY ECOSYSTEM PLAYERS 140

7.1 PGX ECOSYSTEM PLAYERS: OVERVIEW 141

7.2 MARKET SEGMENTATION BY ECOSYSTEM PLAYERS 143

7.2.1 MARKET INSIGHTS & STATISTICS 144

7.3 DIAGNOSTIC TEST COMPANIES 145


7.3.2 MARKET STATISTICS 146

7.3.3 DIAGNOSTIC COMPANIES:DRIVERS & CHALLENGES 147

7.3.4 RECENT KEY DEVELOPMENTS 148

7.3.5 KEY PLAYERS 149


TABLE OF CONTENT


7.4 PHARMACEUTICALS COMPANIES 150



7.4.3 DRUG DEVELOPMENT PROCESS 152

7.4.4 ROLE OF PHARMACEUTICAL COMPANIES & EXAMPLE OF SOME DRUGS 153

7.4.5 PHARMACEUTICALS COMPANIES: DRIVERS & CHALLENGES 154



7.5 SERVICE PROVIDERS 156



7.5.3 SERVICE PROVIDER: ROLES & BIG DATA BENEFITS 158

7.5.4 BIG DATA COMPANIES: DRIVERS & CHALLENGES 159




TABLE OF CONTENT


8 GLOBAL PHARMACOGENOMICS MARKET BY THERAPEUTIC APPLICATIONS 162

8.1 MARKET SEGMENTATION 163

8.2 MARKET STATISTICS 164

8.3 CANCER/ONCOLOGY 165

8.3.1 KEY INSIGHTS & STATISTICS 165


8.3.3 TYPES OF CANCER 167

8.3.4 CANCER: EXAMPLES OF SOME DRUGS 168

8.3.5 CANCER: EXAMPLES OF SOME TESTS 169

8.3.6 MARKET DYNAMICS & KEY PLAYERS 170


8.4 CARDIOVASCULAR DISEASES (CVD) 173




TABLE OF CONTENT


8.4.3 CVD: EXAMPLES OF SOME DRUGS 175

8.4.4 CVD: EXAMPLES OF SOME TESTS 176

8.4.5 RECENT KEY DEVELOPMENTS & KEY PLAYERS 176

8.5 CENTRAL NERVOUS SYSTEM(CNS) 177



8.5.3 CNS: EXAMPLES OF SOME DRUGS 179

8.5.4 CNS: EXAMPLES OF SOME TESTS 180


8.6 INFECTIOUS DISEASES 181



8.6.3 INFECTIOUS DISEASES : EXAMPLES OF SOME DRUGS 183


TABLE OF CONTENT



8.7 OTHER DISEASES 185



8.7.3 OTHER DISEASES : EXAMPLES OF SOME DRUGS 187

8.7.4 OTHER DISEASES : EXAMPLES OF SOME TESTS 188


9 GLOBAL PHARMACOGENOMICS MARKET BY GEOGRAPHY 190

9.1 GEOGRAPHICAL SCENARIO 191

9.2 MARKET INSIGHTS & STATISTICS 193

9.3 NORTH AMERICA 195

9.3.1 MARKET SCOPE 195

9.3.2 NORTH AMERICA: MARKET INSIGHTS & STATISTICS 196


TABLE OF CONTENT


9.3.3 NORTH AMERICAN MARKET DYNAMICS 199

9.3.4 KEY REGULATORY BODIES & ASSOCIATIONS 200

9.3.5 THE U.S. 201

9.3.5.1 THE U.S.: MARKET STATISTICS 202

9.3.5.2 THE U.S.: KEY INSIGHTS 203

9.3.6 CANADA 204


9.4 EUROPE 207


9.4.2 EUROPE: MARKET INSIGHTS & STATISTICS 209

9.4.3 EUROPEAN MARKET DYNAMICS 212

9.4.4 KEY REGULATORY BODIES & ASSOCIATIONS 213

9.4.5 THE U.K. 214

9.4.6 GERMANY 215


TABLE OF CONTENT



9.5 ASIA-PACIFIC (APAC) 217


9.5.2 APAC: MARKET INSIGHTS & STATISTICS 218

9.5.3 APAC MARKET DYNAMICS 221

9.5.4 CHINA 222

9.5.5 JAPAN 224

9.5.6 INDIA 225


9.6 REST OF THE WORLD (ROW) 228

9.6.1 ROW: MARKET INSIGHTS & STATISTICS 228

9.6.2 MIDDLE EAST 231

9.6.3 SOUTH AMERICA 234

9.6.4 AFRICA 236


TABLE OF CONTENT


9.6.5 RECENT KEY DEVELOPMENT 238

10 COMPANY OVERVIEW 239

10.1 ABBOTT LABORATORIES 240

10.1.1 OVERVIEW 240

10.1.2 FINANCIALS 241

10.1.3 FINANCIAL SUMMARY 242

10.1.4 KEY DEVELOPMENTS 243

10.1.5 SWOT ANALYSIS 245

10.2 AFFYMETRIX, INC. 246

10.2.1 OVERVIEW 246






TABLE OF CONTENT


10.3 ASSUREX HEALTH, INC. 251

10.3.1 OVERVIEW 251



10.4 ASTRAZENECA 255

10.4.1 OVERVIEW 255





10.5 ILLUMINA, INC. 261

10.5.1 OVERVIEW 261



TABLE OF CONTENT





10.6 LABORATORY CORPORATION OF AMERICA HOLDINGS 267

10.6.1 OVERVIEW 267

10.6.2 FINANCIALS & FINANCIAL SUMMARY 268



10.7 MYRIAD GENETICS, INC. 271

10.7.1 OVERVIEW 271




10.8 PFIZER, INC. 276


TABLE OF CONTENT


10.8.1 OVERVIEW 276





10.9 QIAGEN, INC. 281

10.9.1 OVERVIEW 281





10.10 ROCHE HOLDING AG-BR 287

10.10.1 OVERVIEW 287


TABLE OF CONTENT






10.11 TEVA PHARMACEUTICAL INDUSTRIES LTD. 293






10.12 THERMO FISHER SCIENTIFIC 299





TABLE OF CONTENT




10.13 TRANSGENOMIC, INC. 306





10.14 OTHER EMERGING COMPANIES 310

10.14.1 DIAGNOSTIC TEST COMPANIES 310

10.14.1.1 COMPANIONDX REFERENCE LAB, LLC 310

10.14.1.2 MAPMY GENOME 310

10.14.1.3 ASURAGEN 310

10.14.1.4 23ANDME 311

10.14.1.5 CNSDOSE 311

10.14.2 PHARMACEUTICAL COMPANIES 312


TABLE OF CONTENT


10.14.2.1 ACTINIUM PHARMACEUTICALS, INC 312

10.14.2.2 FOUNDATION MEDICINE 312

10.14.3 SERVICE PROVIDERS 313

10.14.3.1 PGX SOFTWARE LLC 313

10.14.3.2 GENE LOGIC 313

10.14.3.3 GENEWIZ 313

10.14.3.4 CONATUS CONSULTING, LLC 314

10.14.4 CARE PROVIDERS 315

10.14.4.1 GENE DX 315

10.14.4.2 MAYO CLINIC 315

11 LIST OF ACRONYMS 316


Contact: [email protected] 23

SR. NO LIST OF FIGURES PAGE NO.

1 YEAR CONSIDERATION 40

2 MARKET CLASSIFICATION & SEGMENTATION 41

3 RESEARCH METHODOLOGY 42

4 GLOBAL PHARMACOGENOMICS MARKET ($BILLION) 52

5 GLOBAL PHARMACOGENOMICS MARKET VALUE, 2015-2022 ($BILLION) 52

6 GLOBAL PGX MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION) 53

7 GLOBAL PGX MARKET SHARE, BY THERAPEUTIC APPLICATION, 2015-2022 ($BILLION) 53

8 GLOBAL PHARMACOGENOMICS MARKET, BY GEOGRAPHY-2022 54

9 MECHANISM OF ACTION 58

10 ROLE OF COMPANION DIAGNOSTICS IN PGX 59

11 ROLE OF BIOMAKERS IN PGX 60

12 ROLE OF MOLECULAR DIAGNOSTICS IN PGX 61

13 BENEFITS OF PGX 62

14 END-USE APPLICATIONS OF PGX 63

15 MARKET DYNAMICS 64

LIST OF FIGURES



16 PARTNERSHIPS, JOINT VENTURES AND COLLABORATIONS: KEY PLAYERS ANALYSIS 73

17 PRODUCT LAUNCH AND DEVELOPMENTS: KEY PLAYERS ANALYSIS 77

18 PATENTS, LICENSING, CERTIFICATION AND APPROVALS : KEY PLAYERS ANALYSIS 81

19 MERGERS AND ACQUISITIONS: KEY PLAYERS ANALYSIS 85

20 BUSINESS CONTRACTS AND BUSINESS EXPANSIONS : KEY PLAYERS ANALYSIS 88

21 OTHERS STRATEGIES: KEY PLAYERS ANALYSIS 91

22 PORTER’S FIVE FORCES ANALYSIS 94

23 THREAT OF SUBSTITUTES 95

24 THREAT OF NEW ENTRANTS 97

25 BARGAINING POWER OF BUYERS 99

26 BARGAINING POWER OF SUPPLIERS 101

27 INTENSITY OF COMPETITIVE RIVALRY 103

28 ROLES AND RESPONSIBILITIES OF HEALTHCARE POLICY MAKERS 112

29 ROLE OF FDA IN PGX 119

30 CLASSIFICATION OF MEDICAL DEVICES 120

LIST OF FIGURES



31 EXAMPLE OF SOME COMMON ACTS 121

32 EXAMPLE OF SOME CERTIFICATIONS 122

33 VALUE CHAIN ANALYSIS 123

34 GLOBAL PGX MARKET BY TECHNOLOGY 125

35 GENERALIZED PROCESS FOR THE MICROARRAY 127

36 DIFFERENT TYPES OF MICROARRAYS 127

37 APPLICATIONS OF MICROARRAYS 127

38 MICROARRAY- DRIVERS & CHALLENGES 128

39 SEQUENCING TECHNOLOGIES IN PGX 129

40 SEQUENCING - DRIVERS & CHALLENGES 130

41 APPLICATIONS OF SEQUENCING 130

42 NGS- DRIVERS & CHALLENGES 132

43 APPLICATIONS OF NGS 133

44 GENERALIZED PROCESS FOR PCR 135

LIST OF FIGURES



45 DIFFERENT TYPES OF PCR 136

46 PCR - DRIVERS & CHALLENGES 137

47 APPLICATIONS OF PCR 137

48 APPLICATIONS OF MASS SPECTROMETRY 138

49 APPLICATIONS OF ELECTROPHORESIS 139

50 OVERVIEW OF PGX ECOSYSTEM PLAYERS 141

51 GLOBAL PGX MARKET BY ECOSYSTEM PLAYERS 143

52 GLOBAL PHARMACOGENOMICS MARKET, BY ECOSYSTEM , 2015-2022 ($BILLION) 144

53 GLOBAL PGX ECOSYSTEM MARKET, BY DIAGNOSTIC TESTS COMPANIES, 2015-2022 ($BILLION) 145

54 GLOBAL PGX DIAGNOSTIC TESTS MARKET, BY THERAPEUTIC APPLICATIONS, 2015-2022 ($BILLION) 146

55 GLOBAL PGX DIAGNOSTIC TESTS MARKET, BY GEOGRAPHY, 2015-2022 ($BILLION) 146

56 DIAGNOSTIC COMPANIES- DRIVERS & CHALLENGES 147

57 GLOBAL PGX ECOSYSTEM MARKET, BY PHARMACEUTICAL COMPANIES, 2015-2022 ($BILLION) 150

58 GLOBAL PGX PHARMACEUTICAL MARKET, BY THERAPEUTIC APPLICATIONS, 2015-2022 ($BILLION) 151

59 GLOBAL PGX PHARMACEUTICAL MARKET, BY GEOGRAPHY, 2015-2022 ($BILLION) 151

LIST OF FIGURES



60 DRUG DEVELOPMENT PROCESS 152

61 ROLE OF PHARMACEUTICALS COMPANIES 153

62 PHARMACEUTICALS COMPANIES- DRIVERS & CHALLENGES 154

63 GLOBAL PGX ECOSYSTEM MARKET, BY SERVICE PROVIDERS, 2015-2022 ($BILLION) 156

64 GLOBAL PGX SERVICE PROVIDERS MARKET, BY THERAPEUTIC APPLICATIONS, 2015-2022 ($BILLION) 157

65 GLOBAL PGX SERVICE PROVIDERS MARKET, BY GEOGRAPHY, 2015-2022 ($BILLION) 157

66 THREE DATA DRIVERS OF PGX MARKET 158

67 BENEFITS OF BIG DATA 158

68 BIG DATA COMPANIES- DRIVERS & CHALLENGES 159

69 GLOBAL PGX MARKET BY THERAPEUTICS APPLICATIONS 163

70 GLOBAL PGX MARKET, BY THERAEUTICS APPLICATION, 2015-2022 ($BILLION) 164

71 GLOBAL PGX MARKET BY ONCOLOGY,2015-2022($BILLION) 165

72 GLOBAL PGX ONCOLOGY MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION) 166

73 GLOBAL PGX ONCOLOGY MARKET, BY GEOGRAPHY, 2015-2022 ($BILLION) 166

74 TYPES OF CANCER 167

LIST OF FIGURES



75 ONCOLOGY MARKET DYNAMICS 170

76 GLOBAL PGx MARKET BY CVD, 2015-2022 ($BILLION) 173

77 GLOBAL PGx CVD MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION) 174

78 GLOBAL PGx CVD MARKET, BY GEOGRAPHY, 2015-2022 ($BILLION) 174

79 GLOBAL PGx MARKET BY CNS, 2015-2022 ($BILLION) 177

80 GLOBAL PGx CNS MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION) 178

81 GLOBAL PGx CNS MARKET, BY GEOGRAPHY, 2015-2022 ($BILLION) 178

82 GLOBAL PGx MARKET BY INFECTIOUS DISEASES, 2015-2022 ($BILLION) 181

83 GLOBAL PGx INFECTIOUS DISEASES MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION) 182

84 GLOBAL PGx INFECTIOUS DISEASES MARKET, BY GEOGRAPHY, 2015-2022 ($BILLION) 182

85 GLOBAL PGx MARKET BY OTHER DISEASES, 2015-2022 ($BILLION) 185

86 GLOBAL PGx OTHER DISEASES MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION) 186

87 GLOBAL PGx OTHER DISEASES MARKET, BY GEOGRAPHY, 2015-2022 ($BILLION) 186

88 GROWTH TRAJECTORY OF PGX MARKET 192

89 GLOBAL PHARMACOGENOMICS MARKET, BY GEOGRAPHY , 2015-2022 ($BILLION) 193

LIST OF FIGURES



90 GLOBAL PHARMACOGENOMICS MARKET, BY GEOGRAPHY (2015) 193

91 NORTH AMERICAN PGX MARKET, 2015 197

92 NORTH AMERICAN PGX MARKET, 2015-2022 ($BILLION) 197

93 NORTH AMERICAN PHARMACOGENOMICS MARKET, BY COUNTRY WISE, 2015-2022 ($BILLION) 198

94 NORTH AMERICAN PHARMACOGENOMICS MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION) 198

95 NORTH AMERICAN PHARMACOGENOMICS MARKET, BY THERAPEUTIC APPLICATIONS, 2015-2022 ($BILLION) 198

96 NORTH AMERICAN MARKET DYNAMICS 199

97 KEY REGULATORY BODIES & ASSOCIATIONS 200

98 THE U.S. PGX MARKET, 2015-2022 ($BILLION) 201

99 THE U.S. PHARMACOGENOMICS MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION) 202

100 THE U.S. PHARMACOGENOMICS MARKET, BY THERAPEUTIC APPLICATIONS, 2015-2022 ($BILLION) 202

101 CANADA PGX MARKET DYNAMICS 204

102 EUROPEAN PGX MARKET, 2015 210

103 EUROPEAN PGX MARKET,2015-2022($BILLION) 210

LIST OF FIGURES



104 EUROPEAN PHARMACOGENOMICS MARKET, BY COUNTRY WISE, 2015-2022 ($BILLION) 211

105 EUROPEAN PHARMACOGENOMICS MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION) 211

106 EUROPEAN PHARMACOGENOMICS MARKET, BY THERAPEUTIC APPLICATIONS, 2015-2022 ($BILLION) 211

107 EUROPEAN MARKET DYNAMICS 212

108 KEY REGULATORY BODIES & ASSOCIATIONS 213

109 THE U.K. PGX MARKET, 2015-2022 ($BILLION) 214

110 THE GERMANY PGX MARKET, 2015-2022 ($BILLION) 215

111 APAC COUNTRY-WISE CAGR OF PGX MARKET 219

112 APAC PGX MARKET, 2015-2022 ($BILLION) 219

113 APAC PHARMACOGENOMICS MARKET, BY COUNTRY WISE, 2015-2022 ($BILLION) 220

114 APAC PHARMACOGENOMICS MARKET,BY ECOSYSTEM, 2015-2022 ($BILLION) 220

115 APAC PHARMACOGENOMICS MARKET, BY THERAPEUTIC APPLICATIONS, 2015-2022 ($BILLION) 220

116 APAC MARKET DYNAMICS 221

117 THE CHINA PGX MARKET, 2015-2022 ($BILLION) 222

118 CHINA MARKET DYNAMICS 223

LIST OF FIGURES



119 THE JAPAN PGX MARKET, 2015-2022 ($BILLION) 224

120 THE INDIAN PGX MARKET, 2015-2022 ($BILLION) 225

121 INDIAN MARKET DYNAMICS 226

122 ROW: REGION-WISE CAGR OF PGX MARKET 229

123 ROW PGX MARKET, 2015-2022 ($BILLION) 229

124 ROW PGX MARKET, BY SUB-REGION, 2015-2022 ($BILLION) 230

125 ROW PGX MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION) 230

126 ROW PGX MARKET, BY THERAPEUTICS, 2015-2022 ($BILLION) 230

127 MIDDLE EAST PGX MARKET, 2015-2022 ($BILLION) 231

128 SOUTH AMERICAN PGX MARKET, 2015-2022 ($BILLION) 234

129 AFRICAN PGX MARKET, 2015-2022 ($BILLION) 236

130 ABBOTT LABORATORIES, INC.– OVERALL FINANCIALS, 2013-2015 ($BILLION) 241

131 ABBOTT LABORATORIES, INC.- FINANCIALS BY BUSINESS SEGMENTS, 2013-2015 ($BILLION) 241

132 ABBOTT LABORATORIES, INC.– FINANCIALS BY GEOGRAPHY, 2013-2015 ($BILLION) 241

133 ABBOTT LABORATORIES, INC.- SWOT ANALYSIS 245

134 AFFYMETRIX, INC.– OVERALL FINANCIALS, 2013-2015 ($MILLION) 247

LIST OF FIGURES



135 AFFYMETRIX, INC.- FINANCIALS BY BUSINESS SEGMENTS, 2013-2015 ($MILLION) 247

136 AFFYMETRIX, INC.– FINANCIALS BY GEOGRAPHY,2013-2015 ($MILLION) 247

137 AFFYMETRIX, INC.- SWOT ANALYSIS 250

138 ASSUREX HEALTH, INC.- SWOT ANALYSIS 254

139 ASTRAZENECA – OVERALL FINANCIALS, 2013-2015 ($BILLION) 256

140 ASTRAZENECA- FINANCIALS BY BUSINESS SEGMENTS, 2013-2015 ($BILLION) 256

141 ASTRAZENECA– FINANCIALS BY GEOGRAPHY,2013-2015 ($BILLION) 256

142 ASTRAZENECA- SWOT ANALYSIS 260

143 ILLUMINA, INC.– OVERALL FINANCIALS, 2013-2015 ($MILLION) 262

144 ILLUMINA, INC.- FINANCIALS BY BUSINESS SEGMENTS, 2013-2015 ($MILLION) 262

145 ILLUMINA, INC.– FINANCIALS BY GEOGRAPHY, 2013-2015 ($MILLION) 262

146 ILLUMINA, INC.- SWOT ANALYSIS 266

147 LABORATORY CORPORATION OF AMERICA HOLDING.- OVERALL FINANCIALS, 2013-2015 ($MILLION) 268

148 LABORATORY CORPORATION OF AMERICA HOLDING—FINANCIALS BY BUSINESS SEGMENTS, 2013-2015 ($ MILLION) 268

149 LABORATORY CORPORATION OF AMERICA HOLDING.- SWOT ANALYSIS 270

LIST OF FIGURES



150 MYRIAD GENETICS, INC.– OVERALL FINANCIALS, 2013-2015 ($MILLION) 272

151 MYRIAD GENETICS, INC.– FINANCIALS BY BUSINESS SEGMENTS, 2013-2015 ($MILLION) 272

152 MYRIAD GENETICS, INC.- SWOT ANALYSIS 275

153 PFIZER, INC.– OVERALL FINANCIALS, 2013-2015 ($BILLION) 277

154 PFIZER,INC. – FINANCIALS BY GEOGRAPHY ,2013-2015 ($BILLION) 277

155 PFIZER, INC.- FINANCIALS BY BUSINESS SEGMENTS, 2014-2015 ($BILLION) 277

156 PFIZER, INC.– FINANCIALS BY BUSINESS SEGMENT, 2013 277

157 PFIZER, INC.- SWOT ANALYSIS 280

158 QIAGEN– OVERALL FINANCIALS, 2013-2015 ($MILLION) 282

159 QIAGEN- FINANCIALS BY BUSINESS SEGMENTS, 2013-2015 ($MILLION) 282

160 QIAGEN– FINANCIALS BY GEOGRAPHY, 2013-2015 ($MILLION) 282

161 QIAGEN- SWOT ANALYSIS 286

162 ROCHE HOLDING– OVERALL FINANCIALS,2013-2015 ($BILLION) 288

163 ROCHE HOLDING- FINANCIALS BY BUSINESS SEGMENTS, 2013-2015 ($BILLION) 288

164 ROCHE HOLDING– FINANCIALS OF DIAGNOSTICS DIVISION BY GEOGRAPHY, 2013-2015 ($BILLION) 288

LIST OF FIGURES



165 ROCHE HOLDING– FINANCIALS OF PHARMACEUTICALS,SEGMENT BY GEOGRAPHY, 2013-2015 ($BILLION) 288

166 ROCHE HOLDING- SWOT ANALYSIS 292

167 TEVA PHARMACEUTICAL LTD.– OVERALL FINANCIALS, 2013-2015 ($BILLION) 294

168 TEVA PHARMACEUTICAL LTD.- FINANCIALS BY BUSINESS SEGMENTS, 2013-2015 ($BILLION) 294

169 TEVA PHARMACEUTICAL LTD.– FINANCIALS BY GEOGRAPHY, 2013-2015 ($BILLION) 294

170 TEVA PHARMACEUTICAL INDUSTRIES LTD.- SWOT ANALYSIS 298

171 THERMO FISHER, INC.- OVERALL FINANCIALS, 2013-2015 ($BILLION) 300

172 THERMO FISHER, INC.— FINANCIALS BY BUSINESS SEGMENTS, 2013-2015 ($BILLION) 300

173 THERMO FISHER, INC.— FINANCIALS BY GEOGRAPHY, 2013-2015 ($BILLION) 300

174 THERMO FISHER SCIENTIFIC, INC.- SWOT ANALYSIS 305

175 TRANSGENOMIC, INC.- OVERALL FINANCIALS,2013-2015 ($MILLION) 307

176 TRANSGENOMIC, INC.- FINANCIALS BY BUSINESS SEGEMENTS, 2013-2015 ($MILLION) 307

177 TRANSGENOMIC, INC.- SWOT ANALYSIS 309

LIST OF FIGURES


SR. NO LIST OF TABLES PAGE NO.

1 COMPETITIVE LANDSCAPE: SOME OF THE KEY PLAYERS 72

2 RECENT PARTNERSHIPS, JOINT VENTURES AND COLLABORATIONS 74

3 RECENT PRODUCT LAUNCH AND DEVELOPMENTS 78

4 RECENT PATENTS, LICENSING, CERTIFICATION AND APPROVALS 82

5 RECENT MERGERS AND ACQUISITIONS 86

6 RECENT BUSINESS CONTRACTS AND BUSINESS EXPANSIONS 89

7 RECENT DEVELOPMENTTS OF OTHER STRATEGIES 92

8 PATENT ANALYSIS OF SOME KEY PLAYERS 106

9 PATENT ANALYSIS OF SOME UNIVERSITY/HOSPITAL/PERSON 109

10 MICROARRAY- RECENT KEY DEVELOPMENTS 128

11 NGS- RECENT KEY DEVELOPMENTS 134

12 DIFFERENCE BETWEEN REALT TIME & DIGITAL PCR 136

13 DIAGNOSTIC TEST COMPANIES- RECENT KEY DEVELOPMENT 148

14 EXAMPLE OF SOME PHARMACOGENOMIC DRUGS 153

15 PHARMACEUTICALS COMPANIES- RECENT KEY DEVELOPMENT 155

LIST OF TABLES



16 SERVICE PROVIDERS- RECENT KEY DEVELOPMENT 160

17 CANCER- EXAMPLES OF SOME DRUGS 168

18 CANCER- EXAMPLES OF SOME TESTS 169

19 ONCOLOGY- RECENT KEY DEVELOPMENTS 171

20 CVD- EXAMPLES OF SOME DRUGS 175

21 CVD- EXAMPLES OF SOME TESTS 176

22 CNS- EXAMPLES OF SOME DRUGS 179

23 CNS- EXAMPLES OF SOME TESTS 180

24 INFECTIOUS DISEASES- EXAMPLES OF SOME DRUGS 183

25 OTHER DISEASES- EXAMPLES OF SOME DRUGS 187

26 NORTH AMERICAN PHARMACOGENOMICS MARKET, BY COUNTRY WISE, 2015-2022 ($BILLION) 196

27 NORTH AMERICAN PHARMACOGENOMICS MARKET RECENT KEY DVELOPMENTS 205

28 EUROPEAN PHARMACOGENOMICS MARKET, BY COUNTRY WISE, 2015-2022 ($BILLION) 209

29 EUROPEAN PGX MARKET RECENT KEY DEVELOPMENTS 216

30 APAC PHARMACOGENOMICS MARKET, BY COUNTRY WISE, 2015-2022 ($BILLION) 218

LIST OF TABLES



31 APAC PHARMACOGENOMICS MARKET RECENT KEY DEVELOPMENTS 227

32 ROW PHARMACOGENOMICS MARKET,BY SUB-REGION, 2015-2022 228

33 ROW RECENT KEY DEVELOPMENT 238

34 ABBOTT LABORATORIES, INC. RECENT DEVELOPMENTS 243

35 AFFYMETRIX, INC. RECENT DEVELOPMENTS 249

36 ASSUREX HEALTH, INC. RECENT DEVELOPMENTS 252

37 ASTRAZENECA RECENT DEVELOPMENTS 258

38 ILLUMINA, INC. RECENT DEVELOPMENTS 264

39 LABORATORY CORPORATION OF AMERICA HOLDING RECENT DEVELOPMENTS 269

40 MYRIAD GENETICS RECENT DEVELOPMENTS 273

41 PFIZER, INC. RECENT DEVELOPMENTS 279

42 : QIAGEN RECENT DEVELOPMENTS 284

43 ROCHE HOLDING RECENT DEVELOPMENTS 290

44 TEVA PHARMACEUTICAL INDUSTRIES LTD. RECENT DEVELOPMENTS 296

45 THERMO FISHER, INC. RECENT DEVELOPMENTS 302

46 TRANSGENOMIC, INC. RECENT DEVELOPMENTS 308

LIST OF TABLES

1. REPORT OVERVIEW


1.1 REPORT SCOPE 1.1.1 REPORT COVERAGE

The scope of this report is related to a detailed study of the Pharmacogenomics (PGx) market and its solutions. The term Pharmacogenomics (PGx) has been

clearly differentiated from Pharmacogenetics (PGt) while covering the content of the market overview. The study includes an analysis of technologies used in

PGx, type of tests and drugs which are developed by using this PGx technology in the market.

The market analysis includes classification of the PGx market on the basis of ecosystem players, therapeutic applications, technologies and geographical region.

Technology providers are considered in the diagnostic test companies while biotechnology companies are considered in both pharmaceutical companies and

diagnostic companies sections. The primarily reason for this is the involvement of biotechnology companies in both testing and drug development process. These

companies are involved in research and development processes focusing toward development of new pharmacogenomic solutions. Also examples of some

biomarker, companion diagnostics and molecular tests has been included in diagnostic segment to highlight their importance in pharmacogenomics.

Moreover, the competitive insight section presents detailed insights into the trend followed in the PGx market using the competitive landscape and the Porter’s

Five Force model. Additionally, it includes market dynamics (market drivers, opportunities and challenges) and competitive insights (recent key developments

such as product launch, partnerships, collaboration, and patent analysis among others. It also includes a sub-section of regulatory bodies, consortiums and

alliances which covers major compliances, regulations and certifications that are playing a vital role into this industry.

The market has also been analyzed for the key application areas and key participants in the global PGx market. The market size and Compound Annual Growth

Rate (CAGR) have been estimated considering and analyzing the key players and their revenues. The PGx ecosystem chapter presents an exhaustive overview

of the activities being undertaken by various stakeholders. The chapter on PGx Therapeutics Type is divided further into major disease category in which PGx is

applied. The report proceeds by describing the different types of technologies such as PCR, Microarray analysis, and Next-gene Sequencing among others have

been also discussed in detail. This market study also includes a detailed analysis of the market size, growth opportunities, and trends across major geographies.


FIGURE: YEAR CONSIDERATION

CURRENCY CONVERSION

LIMITATIONS• Technologies currently utilized are expected to persist through the forecast

period with no major breakthrough in technology

• The economic downturn in the future forecast period was not taken under

consideration for market estimation and forecast

•Government organizations and Academic institutions are important stake-

holders in the overall ecosystem and influence the PGx solutions deployment

by other ecosystem players. However, from the point of view of revenue

generation, it is not included in the ecosystem of PGx market in this report.

•Biotechnology companies are included in both the pharmacogenomic test

developers and drug producers depending upon their functions in research

and development

Note: The market values have been rounded off till the second decimal. Due to this, there may be a slight difference in the actual total and the total mentioned in table and figures.

•The base currency considered for this study is U.S. $

•In company profiles section, for the companies having revenues in any other

currencies, is converted in the U.S. $ as per annual conversion rate

• Currencies other than U.S. $ are converted to U.S. $ for all statistical

calculations considering the average conversion rate for the particular year

•Currency conversion rate is taken from historical exchange rate of Oanda

website

1.1.2 ASSUMPTIONS AND LIMITATIONS


2015

BASE YEAR

2016

ESTIMATED YEAR

2016-2022

FORECAST PERIOD

ECOSYSTEM PLAYERS TYPE

Pharmaceutical Companies

Diagnostic Test Developers

Service Providers

THERAPEUTICS APPLICATION TYPESOncology/Cancer

Cardiovascular

Diseases (CVD)

Central Nervous

System Diseases(CNS)

Infectious Diseases

Others

TECHNOLOGY TYPES(QUALITATIVE)

Microarray Analysis

Sequencing

Polymerase Chain

Reaction

Others

GEOGRAPHY

North America

Europe

Asia Pacific (APAC)

Rest of the World (ROW)

1.1.3 MARKET CLASSIFICATION & SEGMENTATION

GLOBAL PHARMACOGENOMICS

MARKET

FIGURE: MARKET CLASSIFICATION & SEGMENTATION

Source: BIS Research Analysis


Data Presentation

1.2 RESEARCH METHODOLOGY


FIGURE: RESEARCH METHODOLOGY

Bottom-Up

Top-Down

Scope Definition Research Design

Data Validation Data Analysis Data Collection

Primary Data

Secondary Data

Primary Interviews/Secondary Research

Market Study

Qualitative Quantitative

Data Presentation


MARKET DRIVERS•Advancement In Technologies•Increasing Cases Of Adverse Drug Reactions(ADRs)•Increasing Genetic Disorders And Congenital Disorders•Government Support & Initiatives•Integration Of Big Data With Pharma & Biotech Companies

MARKET RESTRAINTS:• Time Taking Process Of PGx Drug

and Test Development & Their Approvals

• Lack Of Technical Know-how About Tests And Techniques

• Social And Ethical Issues• Lack Of Proper Reimbursement

Policies• High Cost Of Gene Testing And

Diagnosis

MARKET OPPORTUNITIES:

• Introduction Of PGx Solutions In Developing Economies

• Effective Tool For Clinical Trials• Increasing Applications In

Precision Medicine, Liquid Biopsy, And Robotics

• AGREEMENTS, COLLABORATIONS, & PARTNERSHIPS:

• NEW PRODUCT LAUNCHES

CURRENT MARKET INFORMATION AND DATA

WINNING IMPERATIVESSUPPLY AND DEMAND SIDE FACTORS

GEOGRAPHIC USAGE PATTERN

INFLUENCING FACTORS (Market Trends and Dynamics)

MARKET SIZE & SHARE ANALYSIS

MARKET SIZE & FORECAST:• Global• By Technology• By Ecosystem Players • By Therapeutic Application• By Geography

Arrive at the Market Size, Share, and CAGR for

the Global PGx market

MARKET SIZE

INDUSTRY TRENDSEVOLUTION CUSTOMER ANALYSIS

MARKET SHARE

COMPANY DEVELOPMENTSUPPLY &VALUE CHAIN

PRICING INFO

COMPETITIVE LANDSCAPE

HIGH GROWTH SEGMENTS

FORECAST PERIOD (2016-2022)

1.2.1 DATA POINTS CONSIDERED FOR MARKET SIZE ESTIMATION


KEY DATA POINTSPARAMETERSTYPES

PGx market by region: North America, Europe,

APAC and ROW Overall market and sub-segments in 2015

CAGR of each region in the forecast period

GEOGRAPHIC SPLIT

Region wise PGx market

Revenue of Pharmacogenomics drugs, software and

tests

Revenue generated from different therapeutics by

utilizing PGx solutions

Leading players and their financials

Global market size for the year 2014 and

2015

CAGR for the forecast period (2016– 2022)MARKET SIZE

Ecosystem includes revenue of pharmaceutical,

biotechnology, diagnostic and healthcare IT

companies

Therapeutic covers cancer, cardiovascular, CNS,

Infectious and other diseases

Technology section includes PCR, Microarray, NGS,

and other sequencing technologies

Geography: North America, Europe, APAC and ROW

Global PGx Market by Ecosystem

Global PGx Market by Technology

Global PGx Market By Therapeutics

Global PGx Market by Geography

MARKET SPLIT

1.2.2.1 Key Data Points From Primary Sources


1.2.2 KEY DATA POINT SOURCES

PARAMETERS SOURCES

MARKET SIZE(Value & Volume)

• Company Financials

• Associations

• Magazines & Journals

• Press Releases

• Paid Databases, and

• The BIS Data Repository

REVENUE OF COMPANIES

• Annual Reports

• Investors Presentations

• SEC Filings

• Public Databases, and


QUALITATIVE INFORMATION (Market Dynamics,

Market Trends)

• Company Websites

• Annual Reports

• Press Releases, and


1.2.2.2 Key Data Points From Secondary Sources


1.2.2 KEY DATA POINT SOURCES


SECONDARY SOURCESPRIMARY SOURCES

Annual Reports, SEC Filings, Investor

Presentations, Websites and Press Releases of

top players, News Articles, Journals, and Paid

Databases

• National Institute of Health(NIH)

• Center for Disease Control(CDC)

• Food Drug and Administration(FDA)

• American Congress of Obstetricians and

Gynecologists

• American College of Medical Genetics and

Genomics (ACMG)

• American medical Association(AMA)

• International Federation of Human Genetics

Societies(IFHGS)

• International Genetic Alliance (IGA)

• International Medical Device Regulators Forum

(IMDRF)

• Many Others

DEMAND SIDE:

Interviews with:

• Hospitals providing PGx Solutions

• Senior management & Faculty of several

Academic Institutions

SUPPLY SIDE:

Interviews with:

• Top management of companies like:-

PGx Tests Developers

Drugs Producers

Systems & Databases Developers

Genetic Counselors

Others

Key Players Competitive Landscape

Influencing Factors

Opportunities/

Challenges

Market Estimates

Market Size and Market Share

Geographical

Analysis

Data collected includes :

Market Trends

Primary Sources

Secondary Sources

DATA TRIANGULATION

1.2.3 DATA TRIANGULATION

SOURCES

1.2.1


The Global Market Size is Validated Through Primaries (Demand & Supply Side Experts)

Secondary: Annual Reports, Presentations, Press Release, Journals, Paid Databases, and BIS Research Repository Primary: Demand & Supply Side Experts

Secondary: Annual Reports, Presentations, Press Release, Journals, Paid Databases, and BIS Research Repository Primary: Demand & Supply Side Experts

Primary: Demand & Supply Side ExpertsSecondary: Company Websites, Press Releases, and News Articles

Top-Down Approach (Segmental Analysis) Global PGx Market

Total Global PGx Market ($Billion)

Percent split for the different classifications of the Global PGx

Market (Ecosystem, Therapeutic

Applications & Geography)

Percent split by segments of each

classification

Diagnostic test companies,

pharmaceutical companies,

and service providerssplit

1.2.4 TOP-DOWN APPROACH


Total Market Size ($Billion) = Revenue from Diagnostic Test Companies +

Revenue from Pharmaceuticals + Revenue from Service Providers

Revenue split into diagnostic test companies, pharmaceutical

companies, and service providers

Revenue of top ten players of pharmacogenomic market

Revenue of PGx solution developers

Primary: Demand & Supply Side ExpertsSecondary: Annual Reports, Presentations, Press Release, Journals, Paid Databases, and BIS Research Repository

Primary: Demand & Supply Side ExpertsSecondary: Annual Reports, Presentations, Press Releases, Journals, Paid Databases, and BIS Research Repository

Bottom-Up Approach (Segmental Analysis) Global PGx Market

Global Market Value

Summation of revenue of

geography and therapeutic applications

Percentage split of each segment of ecosystem by therapeutic applications &

by geography

1.2.5 BOTTOM-UP APPROACH


1.3 REPORT DESCRIPTION

•Rapid advancement and innovation of new healthcare technologies such as next generation sequencing, High Throughput Screening (HTS), and Digital

Polymerase Chain Reaction (PCR) are developing the platform for the growth of Pharmacogenomics (PGx) market. The completion of first human genome

project in 1990s has created the platform for the development of further enhanced Pharmacogenomics solutions. PGx is not a modernized market but the

increasing demand for precision medicine, targeted therapeutics and increasing cases of adverse drug reactions are some of the major factors which led to a

tremendous growth rate in the past few years.

•Since the announcement of ‘Precision Medicine Initiative’ by the President Barack Obama in January 2015, a large number of Research and Development

(R&D) programs has been taken up for the developing precise drugs, targeted therapeutics, and laboratory tests which required Pharmacogenomics analysis.

At present, government initiatives are focused towards launching a large number of PGx test & drugs, controlling the increasing level of genetic disorders,

and integrating advanced technologies to fulfill the unmet needs of the patients. Most of the developments taking place in the present scenario are mainly

related to oncology & cardiovascular diseases, but it is anticipated that it may target almost all therapeutic areas affected by genetic mutations.

•Government regulations and standards are sustaining the growth and development of the PGx market. The main aim of these regulations is to make the PGx

solutions more adaptable and focused toward oncology, pain management, CNS, CVD, and infectious diseases among others. The patients are benefitted

indirectly by these regulations as it save time and cut-down cost as the patients get the required treatment for the specific disease. The market growth is

propelled due to factors such as: rising usage in drug discovery processes, increasing demand for pharmacogenomics & precise drugs, technological

innovation and advancement, increasing genetic disorder/abnormalities, and government support and regulations.

•This study includes an overview and analysis of the PGx market, by type of ecosystem players ,type of therapeutics application, technology type, and

geographical regions; allowing the researcher to develop a comprehensive outlook of the market. The PGx market report presents a detailed analysis of the

key market dynamics and provides an extensive insight into various forms of developments, trends and key participants. All of the above mentioned report

coverage parameters are discussed across different regions like North America, Europe, Asia Pacific (APAC), and Rest of the World (ROW).

•While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent

consortiums, compliances, and regulatory bodies, and their involvement in the PGx market. The research incorporates Porter’s Five Forces Model for in-depth

analysis of the PGx market and an assessment of the factors governing it.


What are the major market drivers, challenges and opportunities of the PGx market and their use cases?

What are the key trends and developments in the PGx market for genetic disease management?

What are the key developmental strategies in different therapeutics across all regions?

What are different types of PGx drugs and tests which are available in the market?

How will the key market players leverage on key developments such as Mergers and Acquisitions, Partnerships, and Product Launch among others?

Which geographical region will lead the global PGx market by the end of the forecast period?

Which different technologies are used to develop PGx solutions?

Who are the key players in the PGx market?

What are the government regulations for different PGx solutions?

What are different types of therapeutics in PGx market and which type of PGx product used in their treatment?

What is the different used case scenarios considered under different therapeutic applications?

What are the PGx market trends and key developments in different geographical regions?

KEY QUESTIONS ANSWERED IN THE REPORT


2. EXECUTIVE SUMMARY

2.1 GLOBAL MARKET SCENARIO

ATTRACTIVE MARKET OPPORTUNITIES

• The global Pharmacogenomics (PGx) market growth is gaining speed as

large number of government initiatives and research & development

programs has been launched in the recent years.

• Advancement and innovation of new healthcare technologies such as

next generation sequencing, high throughput screening (HTS), and Digital

PCR are developing the platform for the growth of Pharmacogenomics

(PGx) market. The global PGx market is expected to grow over $XX billion

by 2022.

•The market growth is propelled due to factors such as: rising usage in

drug discovery processes, increasing demand for pharmacogenomics &

precise drugs, technological innovation and advancement, increasing

genetic disorder/abnormalities, and government support and regulations.

•The report has been further classified on the basis of ecosystem players,

therapeutic applications, and geographical regions. Ecosystem is further

segmented in Pharmaceuticals companies, Diagnostic Companies, and

Service Providers which includes Software & Healthcare database

providers, Hospitals & Care Providers and Insurance Providers.

•Diagnostic Test segment is holding the maximum market share and is

expected to grow at XX% CAGR from 2016 to 2022. This is due to the

increasing demand for diagnostic tests as patients are emphasizing more

on pre-diagnosis treatment, increasing genetic disorders & mutational

diseases, and government initiatives and investment in research and

development programs among others.

2015 2022

FIGURE: GLOBAL PHARMACOGENOMICS MARKET ($BILLION)


FIGURE: GLOBAL PHARMACOGENOMICS MARKET VALUE,

2015-2022 ($BILLION)

0.00%

0.00%

0.00%

0.00%

0.00%

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

2015 2016 2017 2018 2019 2020 2021 2022

Global PGx Market Value YOY


KEY INSIGHTS

•Observing current trends, Big Data companies included in service provider

segments are collaborating and entering into partnerships with healthcare

providers, academic institutions, pharmaceuticals and biotechnology

companies to support the growth of the PGx market and thus service segment

is anticipated to grow at a high CAGR of XX% from 2016 to 2022.

•Moreover the Pharmaceutical segment will also gain the traction of the

patients due to increasing awareness about the benefits of PGx solutions and

adoption of these solutions in developing regions.

•With the increasing research and development process, it has been estimated

that the demand for precision drugs will escalate in the coming future and

thus result in the high growth of Pharma & Biotech segment.

•The global PGx market on the basis of therapeutics is classified as

cancer, cardiovascular, central nervous system, infectious diseases and other

diseases. At present, Cancer is dominating the market and is expected to

grow at a CAGR of XX% from 2016 to 2022, as the cases of cancer patients

are increasing every year and thus, deployment of targeted therapeutics and

diagnosis applications of cancer is also anticipated to increase tremendously.

•The primarily reason attributed to the growth of the therapeutics market is

due to the increase in cancer cases, cardiac diseases, skin

diseases, HIVs, mental disorders , and other genetic disorders. However, the

infectious diseases are gaining more traction as compared to other diseases

as the numbers of patients suffering from these diseases are increasing at a

very rapid growth rate all over the world specifically in African and Asian

countries. This segment is growing at a CAGR of XX% from 2016 to 2022.

Source: BIS Research Quantitative Analysis

FIGURE: GLOBAL PGX MARKET SHARE, BY THERAPEUTIC APPLICATION, 2015-2022 ($BILLION)

2.1 GLOBAL MARKET SCENARIOFIGURE: GLOBAL PGX MARKET, BY ECOSYSTEM,

2015-2022 ($BILLION)

-

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

2015 2016 2017 2018 2019 2020 2021 2022

Diagnostic Test Companies Pharmaceutical Companies Service Providers

- 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

2015

2016

2017

2018

2019

2020

2021

2022

Billio

Oncology

Cardiovascular Diseases

Central Nervous System

Infectious Diseases

Others


XX

XX%

XX

XX%

EUROPE

ASIA-PACIFIC

XX

XX%

XX

XX%

NORTH AMERICA

Market Value in Billion (2022)

CAGR% (2016-2022)

SOUTH AMERICA, MIDDLE EAST, AND AFRICA


FIGURE: GLOBAL PHARMACOGENOMICS MARKET, BY GEOGRAPHY- 2022

2.1 GLOBAL MARKET SCENARIO

In North America, existing players are integrating with new start-ups through partnerships and collaboration to capture the North American segment. North

American local players are entering in other developing regions to capture more market share. Throughout the Asia-Pacific and European countries, regulatory

bodies are rolling out regulations to keep a check on latest technologies.

North America is the largest contributor in the revenue generation in PGx market followed by Europe region, and is expected to grow at a high CAGR of XX% CAGR

from 2016 to 2022. APAC region is expected to show the fastest growth globally, and is expected to grow at XX% CAGR from 2016 to 2022.

The APAC region is focusing more on technological development and introduction of new gene sequencing and gene mapping tools into healthcare systems to

develop specific laboratory diagnostic tests.


3. MARKET OVERVIEW

3.1 INTRODUCTION

•Pharmacogenomics was first coined by Friedrich Vogel of Heidelberg

•Pharmacogenomics is the study of drugs effectiveness as per the genomic structure of the patient. These genetic differences in patients indicate that “one

drug does not fit all”, which means that a drug can be safe for one person but harmful for another.

•SAMPLE

• SAMPLE

•SAMPLE

•Pharmacogenomics has two process:

•SAMPLE

•SAMPLE


3.3 ROLE OF COMPANION DIAGNOSTICS IN PGX


Significantly alter the drug development process and commercialization of drug candidates

SAMPLE

SAMPLE

SAMPLE

SAMPLE

SAMPLE

FIGURE: ROLE OF COMPANION DIAGNOSTICS IN PGX


3.6 BENEFITS OF PGx

Tailored treatments and medicines

SAMPLE

SAMPLE

SAMPLE

SAMPLE

SAMPLE

SAMPLE

SAMPLE

FIGURE: BENEFITS OF PGx



3.8 MARKET DYNAMICSFIGURE: MARKET DYNAMICS



RESTRAINTS

CHALLENGESOPPORTUNITIES

OPPORTUNITIES

DRIVERS•Advancement in Technologies

•SAMPLE

•SAMPLE

•SAMPLE

•SAMPLE

D

C

RESTRAINTS

OPPORTUNITIES•Emerging technological Advancement•Availability of Direct to consumer tests•Focus toward pre-implantation genetic diagnosis•Availability of Direct to consumer tests

•Time Taking Process Of PGx Drug and Test Development & their Approvals

•SAMPLE

•SAMPLE

•SAMPLE

•SAMPLE

•SAMPLE

O•SAMPLE

•SAMPLE

•SAMPLE

OPPORTUNITIES


•SAMPLE

•SAMPLE

•SAMPLE

•SAMPLE

•SAMPLE

•SAMPLE

• SAMPLE

•SAMPLE

•SAMPLE

•SAMPLE

•SAMPLE

•The discovery of new genetic markers, gene sequencing & hybridization, companion diagnostics, NGS and

non-invasive techniques are nourishing the growth of PGx market

•SAMPLE

• SAMPLE

•SAMPLE

01

Advancement in Technologies

HIGH

02

SAMPLE

SAMPLE

03

SAMPLE

SAMPLE

3.8.1 MARKET DRIVERS


4. COMPETITIVE INSIGHTS

XX%

BUSINESS EXPANSIONS

& CONTRACTS

XX%

XX%

MERGERS & ACQUISITIONS

XX%OTHERS

XX%PRODUCT

LAUNCHES & DEVELOPMENTS

XX%PARTNERSHIPS & COLLABORATIONS

4.1 KEY MARKET DEVELOPMENTS & STRATEGIES

Note : Others section include , law suit/infringement, awards and recognition, financial investments and financial grants

PATENT, LICENSING,CERTIFICATION & APPROVALS


4.1.1 COMPETITIVE LANDSCAPE OF SOME OF THE KEY PLAYERS

COMPANY NAME PARTNERSHIPS & COLLABORATIONS

PRODUCT DEVELOPMENT &

PRODUCTLAUNCH

PATENTS, LICENSING,

APPROVALS & CERTIFICATION

MERGERS & ACQUISITI

-ONS

BUSINESS CONTRACTS & EXPANSIONS

OTHERS

THERMO FISHER SCIENTIFIC, INC. 3% SAMPLE SAMPLE SAMPLE SAMPLE SAMPLE

SAMPLE SAMPLE SAMPLE SAMPLE SAMPLE SAMPLE SAMPLE










TOTAL 100% 100% 100% 100% 100% 100%

Source : BIS Research AnalysisNote : Others section include , law suit/infringement, awards and recognition, financial investments and financial grants

TABLE: COMPETITIVE LANDSCAPE: SOME OF THE KEY PLAYERS


•SAMPLE

• SAMPLE

• SAMPLE

•SAMPLE

•SAMPLE

4.1.2 PARTNERSHIPS, JOINT VENTURES AND COLLABORATIONS4.1.2.1 KEY INSIGHTS

Myriad Genetics

XX

XX

XX

XX

XX

Source : BIS Research Analysis

FIGURE: PARTNERSHIPS, JOINT VENTURES AND COLLABORATIONS: KEY PLAYERS ANALYSIS (2013-2016)

•This strategy consists of partnerships, collaborations and joint ventures

that companies enter into for the their business expansion and

development. This strategy forms the maximum part of the developments

that are occurring in the market from Jan 2013 to March 2016


DATE STRATEGY KEY DEVELOPMENT

March 2016 Collaboration Teva Pharmaceuticals entered into a research agreement with AbCellera for the identification of rare monoclonal antibodies

SAMPLE SAMPLE SAMPLE






65

Source : BIS Research Analysis

TABLE: RECENT PARTNERSHIPS, JOINT VENTURES AND COLLABORATIONS

4.1.2.2 RECENT PARTNERSHIPS, JOINT VENTURES AND COLLABORATIONS


4.2 PORTER’S FIVE FORCES ANALYSIS

THREAT OFSUBSTITUTES

(XX)

BARGAININGPOWER OF BUYERS

(XX)

INTENSITY OFCOMPETITIVE RIVALRY

(XX)

BARGAINING POWER OF SUPPLIERS

(XX)

THREAT OFNEW ENTRANTS

(XX)


FIGURE: PORTER’S FIVE FORCES ANALYSIS

Factors are rated between 1 to 51 - 2.5: Low 2.5 - 3.5: Moderate3.5 - 5: High


THREAT OF SUBSTITUTES(MODERATE)

• Buyers propensity towards substitute

• SAMPLE

• SAMPLE

• SAMPLE

• SAMPLE

00.5

11.5

22.5

33.5

4

Buyers propensity toward substitute

XX

XX

XX

4.2.1 THREAT OF SUBSTITUTES


FIGURE: THREAT OF SUBSTITUTES


4.2.1 THREAT OF SUBSTITUTES

•Availability of technological advanced products are creating an opportunity for patients•Low cost of substitute and their generic nature

Buyers propensity towards substitute(High-3.6)

•SAMPLE•SAMPLESAMPLE




5. INDUSTRY ANALYSIS

5.1 PATENT ANALYSIS5.1.1 SOME OF THE KEY PLAYERS

COMPANY NAME OF THE PATENT PUBLICATION NUMBER

PUBLICATION DATE

IRM LLC, Novartis AG Markers associated with wnt inhibitors US20160024587A1 28 January 2016

SAMPLE SAMPLE SAMPLE SAMPLE










TABLE: PATENT ANALYSIS OF SOME KEY PLAYERS



Regulatory

bodies/Associations/C

onsortium

Date Region Features

Genetic Testing Laboratories UK

2003 U.K. •Established contacts with many of the British Embassies and High Commissions to arrange collection of samples from applicants overseas in the most expeditious method•Provide legal services




SAMPLE


5.2 REGULATIONS, CONSORTIUMS, CERTIFICATIONS & STANDARDS

• SAMPLE

• SAMPLE

• SAMPLE


SAMPLE

SAMPLE

SAMPLE

SAMPLE

SAMPLE SAMPLE

SAMPLE

PGx Products manufacturers &

Providers

(SAMPLE)

SAMPLE

•SAMPLE

•SAMPLE

•SAMPLEApp

rova

ls fro

m r

egul

ator

y bo

dies


5.3 VALUE CHAIN ANALYSIS

FIGURE: VALUE CHAIN ANALYSIS


6. GLOBAL PHARMACOGENOMICS MARKET BY TECHNOLOGY

GLOBAL PHARMACOGENOMICS MARKET BY TECHNOLOGY

MICROARRAY SEQUENCING

SANGER SEQUENCING PYRO SEQUENCING NEXT-GEN SEQUENCING

POLYMERASE CHAIN REACTION OTHERS

6.1 MARKET SEGMENTATION BY TECHNOLOGY

FIGURE: GLOBAL PGx MARKET BY TECHNOLOGY



•Microarray is a technique used to study the effect of many genes at a time by matching known and unknown gene sequences samples based upon base pairing

rules

•SAMPLE

•SAMPLE

Extraction of The Targeted RNA/DNA SAMPLE SAMPLE SAMPLE SAMPLE

FIGURE: GENERALIZED PROCESS FOR THE MICROARRAY

6 . 2 MICROARRAY6 . 2 . 1 INTRODUCTION



6 . 2 . 2 M I C R O A R R A Y : T Y P E S , A P P L I C A T I O N S &K E Y P L A Y E R S

MM Chips

SAMPLE

SAMPLE

SAMPLE

SAMPLE

FIGURE: DIFFERENT TYPES OF MICROARRAYS FIGURE: APPLICATIONS OF MICROARRAYS


Expression Analysis : measuring the expression of genes

SAMPLE

SAMPLE

SAMPLE

SAMPLE

MICROARRAY APPLICATIONS

Some of the key players are Illumina

Inc., SAMPLE

SAMPLE

Key Players


6 . 2 . 3 M I C R O A R R A Y : M A R K E T D Y N A M I C S &R E C E N T D E V E L O P M E N T S

• No standardized criteria for evaluation of huge amount of data generated

• SAMPLE

RESTRAINTS

SAMPLE

SAMPLE

DRIVERS

FIGURE: MICROARRAY- DRIVERS & CHALLENGES

Company Recent Key Development

SAMPLE SAMPLE

SAMPLE SAMPLE

SAMPLE SAMPLE

TABLE: MICROARRAY- RECENT KEY DEVELOPMENTS



7. GLOBAL PHARMACOGENOMICSMARKET BY ECOSYSTEM PLAYERS



FIGURE: GLOBAL PGx MARKET BY ECOSYSTEM PLAYERS

7.2 MARKET SEGMENTATION BY ECOSYSTEM PLAYERS

GLOBAL PGX MARKET BY ECOSYSTEM

PLAYERS

DIAGNOSTIC TEST COMPANIES

PHARMACEUTICAL COMPANIES

SERVICE PROVIDERS

SOFTWARE AND DATABASE PROVIDERS

INSURANCE PROVIDERS

HOSPITAL & CARE PROVIDERS

79

7 . 2 . 1 M A R K E T I N S I G H T S & S T A T I S T I C S

•The global PGx market is expected to grow at an estimated CAGR of XX% from 2016 to 2022. Diagnostic Test segment is dominating the global market and

accounted for $XX billion in 2015 due to development of large number of diagnostic and genetic tests .These tests help to collect genetic information of the

patients and help the physicians to identify the symptoms for specific disorders. Moreover, the pharmaceutical segment will grow at a CAGR of XX% from

2016 to 2022 to reach $XX billion by the end of the forecast period. Some of the reasons for this high growth include development of more precise diagnostic

tests, many research initiatives in development of precise drugs, and the increasing demand of more personalized healthcare services by the patients.


FIGURE: GLOBAL PGx MARKET, BY ECOSYSTEM , 2015-2022 ($BILLION)

-

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

2015 2016 2017 2018 2019 2020 2021 2022

Diagnostic Test Companies


Service Providers


7 . 3 D I A G N O S T I C T E S T C O M P A N I E S7 . 3 . 1 I N T R O D U C T I O N

•Diagnostic companies are responsible for developing more preciseand

accurate diagnostic tests to benefit patients. With the development of new

molecular diagnostics, the opportunity for early detection of a disease

arises, along with the potential to improve patient care and reduction in

healthcare costs

•SAMPLE

•SAMPLE

•SAMPLE

•SAMPLE

•SAMPLE

•SAMPLE

•SAMPLE

•SAMPLE

•SAMPLE

•SAMPLE

•SAMPLE

•SAMPLE

FIGURE: GLOBAL PGX ECOSYSTEM MARKET, BY DIAGNOSTIC TESTS COMPANIES, 2015-2022 ($BILLION)

-

0.00

0.00

0.00

0.00

0.00

0.00

2015 2016 2017 2018 2019 2020 2021 2022


•Diagnostic test segment accounted for $XX billion in 2015 and is growing at a CAGR

of XX% from 2016 to 2022

•This segment comprised of companies involved in development of tests, assays

and technology platforms for the analysis and sequencing of genes and includes

players such as technology developer, biotechnology companies and diagnostic

companies


7 . 3 . 2 M A R K E T S T A T I S T I C SFIGURE: GLOBAL PGX DIAGNOSTIC TESTS MARKET, BY THERAPEUTIC APPLICATIONS, 2015-2022 ($BILLION)

FIGURE: GLOBAL PGX DIAGNOSTIC TESTS MARKET, BY GEOGRAPHY, 2015-2022 ($BILLION)

- 0.00 0.00 0.00 0.00 0.00 0.00

2015

2016

2017

2018

2019

2020

2021

2022

Oncology



Infectious Diseases

Others

2015 2016 2017 2018 2019 2020 2021 2022

North America Europe Asia-Pacific (APAC) RoW


•In 2015, the Cancer segment dominated the PGx market with the largest

market share, accounting for $XX billion, and is now expected to grow over

$XX billion by the end of 2022.

•While, infectious diseases are expected to grow at a high CAGR of XX% from

2016 to 2022 because of increasing prevalence of many infectious diseases

and advancement of technologies detecting mutant genes and thus help in

the early treatment of neurological diseases.

•However, the other disease segment is growing at the highest CAGR of XX%

from 2016 to 2022

• North America dominated the global PGx market in diagnostic testing and

accounted for $XX billion in 2015 and is growing at a CAGR of XX% from

2016 to 2022

•The APAC is the fastest growing region and will grow over $XX billion by

2022, while growing at a CAGR of XX% from 2016 to 2022 as the concern for

personal healthcare and fitness is increasing with the rise in precision

medicine solutions.


7 . 3 . 3 D I A G N O S T I C C O M P A N I E S : D R I V E R S & C H A L L E N G E S

DRIVERS

• Lack of a well established business models for development of tests

• SAMPLE

• SAMPLE

• SAMPLE

CHALLENGES

• SAMPLE

SAMPLE

SAMPLE

SAMPLE

SAMPLE

FIGURE: DIAGNOSTIC COMPANIES- DRIVERS & CHALLENGES




Thermo Fisher Scientific In April 2015, Thermo Fisher Scientific launched The oncomine Focus Array that enabled simultaneousanalysis of DNA and RNA

• SAMPLE • SAMPLE






• SAMPLE

• SAMPLE

• Some of the key technology providers are - SAMPLE

7.3.4 RECENT KEY DEVELOPMENTS

7.3.5 KEY PLAYERS

TABLE: DIAGNOSTIC TEST COMPANIES- RECENT KEY DEVELOPMENT



8. GLOBAL PHARMACOGENOMICS MARKET BY THERAPEUTIC

APPLICATIONS

Global PGx Market By

Therapeutic Applications

Oncology/Cancer Cardiovascular Diseases


Infectious Diseases Others

FIGURE: GLOBAL PGX MARKET BY THERAPEUTIC APPLICATIONS

8.1 MARKET SEGMENTATION



8.3 CANCER/ONCOLOGY8.3.1 KEY INSIGHTS & STATISTICS

•Cancer is classified to be a disease of genetic mutation, as a resultant of

genetic changes. Technological advancement has generated a better

understanding of tumors and led to more effective treatment strategies that are

personalized to the genetic profile of patients suffering from different types of

cancer.

•The global PGx market for Cancer accounted for $XX billion in 2015 and is

expected to grow to a CAGR of XX% from 2016 to 2022. Many personalized

devices have been developed that help to connect data to a central server that

helps physicians and clinicians in turn to provide feedback to the patients and

provide them specific treatment

•Moreover, the DNA sequencing and analysis of patient’s tumors to discover

genetic alterations related to specific cancers are aimed to encourage further

advancement in PGx. The comprehensive catalogs of the key genomic changes

support generations of more effective ways to diagnose, treat and prevent

cancer.

•The National Center for Toxicological Research (NCTR) which is a functional

unit of FDA, is involved in performing research to improve cancer genomics

knowledge and treatment. Their goal is to establish experimental approaches to

find effectual treatments that obstruct the development of acquired drug

resistance in tumors.

FIGURE: GLOBAL PGx MARKET BY ONCOLOGY,2015-2022 ($BILLION)


-

0.00

0.00

0.00

0.00

0.00

0.00

0.00

2015 2016 2017 2018 2019 2020 2021 2022


In 2015, North America dominated the PGx market with the largest

market share, accounted for $XX billion, and is expected to grow over

$XX billion by 2022. The number of patients suffering with cancer is

increasing year by year all over the world and it is affecting almost

people of all age group. So to overcome this problem PGx solutions are

deployed in huge numbers that is nourishing the growth of the market.

Regardless of this fact, it is foreseen that APAC region will grow at a

high CAGR of XX% from 2016 to 2022.

•Diagnostic tests segment of Cancer therapeutic application dominated

the global market in 2015 and expected to grow over $XX billion by the

end of 2022.

•Service providers will be the fastest growing and will reach over $XX

billion by 2022, while growing at a CAGR of XX% from 2016 to 2022.

• In addition to this, many diagnostic tests and targeted therapies have

been developed to cure cancer patients. .

FIGURE: GLOBAL PGx ONCOLOGY MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION)

FIGURE: GLOBAL PGx ONCOLOGY MARKET, BY GEOGRAPHY, 2015-2022 ($BILLION)

8.3.2 MARKET STATISTICS


-

0.00

0.00

0.00

0.00

0.00

0.00

0.00

2015 2016 2017 2018 2019 2020 2021 2022

Service Providers


Diagnostic Test Companies

2015 2016 2017 2018 2019 2020 2021 2022



DRUG NAME BIOMARKER TYPE COMMENTS

Vemurafenib

(ZelborafTM)BRAF V600E Melanoma

Indicated for the treatment of patients with

unrespectable or metastatic melanoma with BRAF

V600E mutation as detected by an FDA-approved

test

• SAMPLE • SAMPLE • SAMPLE • SAMPLE






8.3.4 CANCER: EXAMPLES OF SOME DRUGSTABLE: CANCER- EXAMPLES OF SOME DRUGS


DRUG NAME TEST /KIT TYPE COMMENTS

Afatinib (Gilotrif) therascreen EGFR RGQ PCR Ki Lung Cancer

Detection of exon 19 deletions and exon 21 (L858R)

substitution mutations of the epidermal growth factor

receptor (EGFR) gene in non-small cell lung cancer

(NSCLC) tumor tissue





8.3.5 CANCER: EXAMPLES OF SOME TESTS

TABLE: CANCER- EXAMPLES OF SOME TESTS




Roche Holding AG-BR In February 2016, Roche received FDA approval for Alecensa that is used for treating patients with anaplastic lymphoma Kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC)

Illumina, Inc. In January 2016, Illumina Inc. formed a new company named GRAIL for detection of early cancer using blood-based screening

Genentech In December 2015, Genentech received FDA approval for Alecensa that was used to treat patients with people with ALK positive metastatic non-small cell lung cancer

AstraZeneca In November 2015, AstraZeneca's TAGRISSO received FDA approval that allowed treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC

Transgenomic, Inc. In November 2015, Transgenomic Inc. launched Multiplexed ICE-COLD PCR (MX-ICP) Non-Small Cell Lung Cancer (NSCLC) Analysis panelfor liquid biopsy detection of key actionable tumor

Myriad Genetics In October 2015, Myriad Genetics entered into a collaboration with Tufts Health Plan that provided coverage of members with localised prostate cancer

Roche Holding AG-BR In September 2015, Roche launched the Cobas EFGR Mutation Test v2, that is the first oncology assay from the company to use either plasma or tumour tissue as a sample

Transgenomic, Inc. In August 2015, Transgenomic Inc. launched MX-ICP GFR Analysis lung cancer panel and provides precision detection levels as low as 0.01%

AstraZeneca In July 2015, AstraZeneca got FDA approval for its IRESSA (gefitinib) tablets, for the first-line treatment of patients with metastatic non-small cell lung cancer

QIAGEN' In July 2015, QIAGEN's therascreen EGFR test received U.S. marketing approval to be used with AstraZeneca's IRESSA for patients with advanced or metastatic non-small cell lung cancer

LABCORP of America In June 2015, LabCorp partnered with Sysmex with an aim to focus on the development of blood-based molecular diagnostic tests to advance precision medicine in oncology

8.3.7 RECENT KEY DEVELOPMENTSTABLE: ONCOLOGY- RECENT KEY DEVELOPMENTS



Roche Holding AG-BR In February 2016, Roche received FDA approval for Alecensa that is used for treating patients with anaplastic lymphoma Kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC)












9. GLOBAL PHARMACOGENOMICS MARKET BY GEOGRAPHY

GLOBAL PHARMACOGENOMICS

MARKET, BY GEOGRAPHY

EUROPE ASIA-PACIFIC REST OF THE WORLD

9 . 1 G E O G R A P H I C A L S C E N A R I O

NORTH AMERICA


INTRODUCTION GROWTH MATURITY DECLINE

• SAMPLE

• SAMPLE

• SAMPLE

• SAMPLE

9 . 1 G E O G R A P H I C A L S C E N A R I O

FIGURE: GROWTH TRAJECTORY OF PGX MARKET



•North America is currently dominating the market and acquires XX% market share, followed by Europe and Asia-Pacific. North American market accounted

for $XX billion in 2015 and is growing at a CAGR of XX% from 2016 to 2022. Increasing usage of Pharmacogenomics in the development of personalized

medicines and high income of patients to afford costly diagnostic and genetic tests are some of the factors which fuel the market growth

•APAC is estimated to grow at the highest CAGR XX% from 2016 to 2022 and is expected to grow over $XX billion by 2022. The primary reasons for a high

growth rate is increasing number of government initiatives, investments plans, and increasing awareness about ADRs among others

FIGURE: GLOBAL PHARMACOGENOMICS MARKET, BY GEOGRAPHY (2015)

9 . 2 M A R K E T I N S I G H T S & S T A T I S T I C S


FIGURE: GLOBAL PHARMACOGENOMICS MARKET, BY GEOGRAPHY , 2015-2022 ($BILLION)

2015 2016 2017 2018 2019 2020 2021 2022



•Rest of the World (ROW) is also expected to have promising market growth for PGx industry with leading diagnostic and

biotechnology companies which are expanding their distribution outlets in markets such as Middle East, Africa, and South

America. Various startups are also emerging in the region with cost effective and innovative products for accelerating the

adoption rate in these regions.

•The U.S. is the country having largest share in the North American PGx market and is expected to grow

over $XX billion by 2022 at compounded annual growth rate (CAGR) of XX% from 2016-2022

•The U.K. is the leading country in Europe which is having the largest share of PGx market

followed closely by the Germany. It is predicted to have a market value of $XX billion by 2022

at compounded annual growth rate (CAGR) of XX% from 2016-2022.

•China, India and Japan are expected to be the key countries in Asia-Pacific region with a high growth

potential for PGx market players. South Korea and Singapore are other emerging countries in the

region. It is expected that China will grow at a compounded annual growth rate (CAGR) of XX% from

2016-2022.

PHARMACOGENOMICS MARKET INSIGHTS BY GEOGRAPHICAL REGION

9 . 2 M A R K E T I N S I G H T S & S T A T I S T I C S


North America

XX% of the Global Pharmacogenomics

Market

The U.S. growing at a high CAGR of

XX% from 2016 to 2022

Some of the key players are LABCORP of America, Roche, Pfizer, Abbott, Affymetrix, Myriad

Genetics, Thermo Fisher , Qiagen,Illumina, GSK, and Novartis among others

NORTH AMERICAN PHARMACOGENOMICS MARKET, BY COUNTRIES, 2015-2022

($BILLION)

NORTH AMERICAN PHARMACOGENOMICS MARKET, 2015-2022 ($BILLION)



9 . 3 . 2 N O R T H A M E R I C A : M A R K E T I N S I G H T S &S T A T I S T I C S

MARKET SHARE OF NORTH AMERICA IN PHARMACOGENOMICS MARKET- 2015

KEY PLAYERS

TABLE: NORTH AMERICAN PHARMACOGENOMICS MARKET,BY COUNTRY WISE, 2015-2022 ($BILLION)

-0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

2015 2018 2022

-

0.00

0.00

0.00

0.00

0.00

0.00

0.00

2015 2018 2022

North America

ROW (apart from North America)

2015 2018 2020 2022 CAGR% (2016-2022)

The U.S. XX XX XX XX XX

Others XX XX XX XX XX

U.S. accounts for

~XX%

FIGURE: NORTH AMERICAN PGx MARKET

CAGR XX%

GRAPH

KEY MARKET INSIGHTS

•North America is growing at a CAGR of XX% from 2016 to 2022 and is

estimated to reach $XX billion by the end of 2022

•The U.S. is dominating this market and growing at a CAGR of XX% from

2016 to 2022 followed by Canada

•North America is home to technological innovations and people are

emphasizing on early detection of disorders and their diagnosis

FIGURE: NORTH AMERICAN PGx MARKET, 2015-2022 ($BILLION)


9.3.2 NORTH AMERICA: MARKET INSIGHTS & STATISTICS

-

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

2015 2016 2017 2018 2019 2020 2021 2022



9.3.2 NORTH AMERICA: MARKET INSIGHTS & STATISTICS

-

0.00

0.00

0.00

0.00

0.00

0.00

0.00

2015 2016 2017 2018 2019 2020 2021 2022

The U.S.

Others

2015 2016 2017 2018 2019 2020 2021 2022

Diagnostic Test Companies Pharmaceutical Companies Service Providers

- 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

2015

2016

2017

2018

2019

2020

2021

2022

Oncology



Infectious Diseases

Others


FIGURE: NORTH AMERICAN PHARMACOGENOMICS MARKET,BY COUNTRY WISE, 2015-2022 ($BILLION)

FIGURE: NORTH AMERICAN PHARMACOGENOMICS MARKET,BY ECOSYSTEM, 2015-2022 ($BILLION)

FIGURE: NORTH AMERICAN PHARMACOGENOMICS MARKET,BY THERAPEUTIC APPLICATIONS, 2015-2022 ($BILLION)

•The U.S. accounted for $XX billion in 2015 and anticipated to dominate the PGx market by the end of forecast period growing at a CAGR of XX% from 2016 to

2022.

•President Obama hosted a summit at the White House on the Precision Medicine Initiative (PMI) on 28 February 2016 that again fuelled the growth of PGx

market

•This high growth is due to large number of healthcare programs that have been deployed into region/countries such as the U.S., Canada, Mexico, Brazil, and

Panama among others.

•The U.S. has been the first choice with regard to a suitable deployment of PGx solutions due to the availability of established healthcare system and

technological advancement including emergence of Direct to Consumer (DTC) tests which is a consumer business of scanning or sequencing genomes for

health-related genetic information

The U.S.

Others

9 . 3 . 5 T H E U . S .

FIGURE: THE U.S. PGX MARKET, 2015-2022 ($BILLION)FIGURE: THE U.S. PGX MARKET, 2015


-

0.00

0.00

0.00

0.00

0.00

0.00

0.00

2015 2016 2017 2018 2019 2020 2021 2022



Almac Group Ltd In February 2016, a patent was assigned to Almac Discovery for its novel therapeutic drug, ALM301 in U.S










9.3.7 RECENT KEY DEVELOPMENTSTABLE: NORTH AMERICAN PHARMACOGENOMICS MARKET RECENT KEY DVELOPMENTS



10. COMPANY OVERVIEW

PARTICULAR SPECIFICATIONS (AS OF 2016)

Website www.abbott.com

Contact Details SAMPLE

Year of Establishment SAMPLE

Ownership Type SAMPLE

Company Type SAMPLE

Number of Employees SAMPLE

Net Revenue SAMPLE

Competitors SAMPLE

Subsidiaries SAMPLE

Related Products & Services SAMPLE

Other Products & Services SAMPLE

Source: Abbott Website, LinkedIn, BIS Research Analysis

10.1 ABBOTT LABORATORIES10.1.1 OVERVIEW


Medical Devices Established Pharmaceuticals

Diagnostics Nutrition

($B

illio

n)

2013

2014

2015

International United States

($B

illio

n)

2013

2014

2015

FIGURE: ABBOTT LABORATORIES, INC.– OVERALL FINANCIALS, 2013-2015 ($BILLION)

FIGURE: ABBOTT LABORATORIES, INC.- FINANCIALS BY BUSINESS SEGMENTS, 2013-2015 ($BILLION)

FIGURE: ABBOTT LABORATORIES, INC.– FINANCIALS BY GEOGRAPHY, 2013-2015 ($BILLION)

Source: : Abbott Annual Report, BIS Research Analysis

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

December'13 December'14 December'15

Net

In

com

e an

d O

per

atin

g I

nco

me

($B

illio

n)

Net

Rev

enu

e ($

Bill

ion

)

10.1.2 FINANCIALS


DATE STRATEGY DESCRIPTION

May 2015 Approval Abbott received CE Mark for the latest advancement of its Absorb stent system that had an aim to help doctors treat people with heart diseases











TABLE: ABBOTT LABORATORIES, INC. RECENT DEVELOPMENTS

Source: Abbott Website, BIS Research Analysis

10.1.4 KEY DEVELOPMENTS


STRENGTHS

• An exclusive license to develop a diagnostic test in

the U.S. based on several new biomarkers

•SAMPLESAMPLESAMPLE

OPPORTUNITIESSAMPLE•SAMPLE

•SAMPLE

•SAMPLE

THREATSSAMPLE SAMPLE

SAMPLE

WEAKNESSSAMPLESAMPLE

S W

O T


FIGURE: ABBOTT LABORATORIES, INC.- SWOT ANALYSIS

10.1.5 SWOT ANALYSIS


PARTICULAR 10.14.1.2 COMPANIONDX

REFERENCE LAB, LLC

10.14.1.2 MAPMY GENOME 10.14.1.3 ASURAGEN

Website www.companiondxlab.com www.mapmygenome.in www.asuragen.com

Contact Details SAMPLE SAMPLE SAMPLE

Year of Establishment SAMPLE SAMPLE SAMPLE

Ownership Type SAMPLE SAMPLE SAMPLE

Company Type SAMPLE SAMPLE SAMPLE

Competitors SAMPLE SAMPLE SAMPLE

Related Products &

Services


Other Products &

Services


Source: Company Website, LinkedIn, BIS Research Analysis

10.14 OTHER SIGNIFICANT PLAYERS10.14.1 DIAGNOSTIC TEST COMPANIES


11. LIST OF ACRONYMS

1 1 . 1 LIST OF ACRONYMS

ACRONYMS DESCRIPTION

3D Three-dimensional

AACR American Association for Cancer Research

SAMPLE SAMPLE

SAMPLE SAMPLE

SAMPLE SAMPLE

SAMPLE SAMPLE

SAMPLE SAMPLE

SAMPLE SAMPLE

SAMPLE SAMPLE

SAMPLE SAMPLE

SAMPLE SAMPLE

SAMPLE SAMPLE

SAMPLE SAMPLE

SAMPLE SAMPLE

SAMPLE SAMPLE

SAMPLE SAMPLE

SAMPLE SAMPLE

SAMPLE SAMPLE

SAMPLE SAMPLE

SAMPLE SAMPLE


GOT QUESTIONS?

BIS Research9100 West Bloomington Freeway,

Suite 159 Bloomington,

MN 55431

U.S.

Tel: +1 650 228 0182

Global Delivery CenterA 21, Kailash Colony,

New Delhi,

India

Tel: +91 11 46120391

THANK YOU


global pharmacogenomics (pgx) market analysis, estimation & forecast 2016-2022

Documents